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Abstract  14 
Regulations dealing with microbicides in Europe and the United States are evolving and now 15 
require data on the risk of resistance development in organisms targeted by microbicidal 16 
products. There is no standard protocol to assess the risk of resistance development to 17 
microbicidal formulations. This study aimed to validate the use of changes in microbicide 18 
and antibiotic susceptibility as initial markers for predicting microbicide resistance and 19 
cross-resistance to antibiotics. Three industrial isolates (Pseudomonas aeruginosa, 20 
Burkholderia cepacia, Klebsiella pneumoniae) and two Salmonella enterica serovar 21 
Typhimurium strains (SL1344 and 14028S) were exposed to a shampoo, a mouthwash, eye 22 
make-up remover and the microbicides contained within these formulations (chlorhexidine 23 
digluconate; CHG and benzalkonium chloride; BZC), under realistic, in-use conditions.  24 
Baseline and post- exposure data were compared. No significant increases in minimum 25 
inhibitory concentration (MIC) or minimum bactericidal concentration (MBC) were 26 
observed in any strain after exposure to the three formulations. Increases in the MIC and 27 
MBC of CHG and BZC of up to 100-fold were observed in SL1344 and 14028S but were 28 
unstable. Changes in antibiotic susceptibility were not clinically significant.  29 
The use of MICs and MBCs combined with antibiotic susceptibility profiling and stability 30 
testing generated reproducible data that allowed for an initial prediction of microbicide 31 
resistance development. These approaches measure characteristics that are directly relevant 32 
to the concern over resistance and cross-resistance development following use of 33 
microbicides. These techniques are low cost and high-throughput, allowing manufacturers to 34 
provide data to support early assessment of risk of resistance development to regulatory 35 
bodies promptly and efficiently. 36 
 37 
Keywords: microbicides, resistance, predictive protocol, regulation 38 
INTRODUCTION 39 
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Microbicides have been extensively used in the control of bacteria for decades, and 40 
are commonly incorporated into a variety of products including disinfectants, 41 
cosmetics, preservatives, pesticides and antiseptics. Despite this ever-increasing use, 42 
bacteria generally remain susceptible to microbicides when they are used correctly. 43 
However, the indiscriminate use of microbicides in a wide range of environments 44 
has raised concerns about the selection of microbicide and antibiotic-resistant 45 
bacteria (1, 2). Despite the establishment of the European Union (EU) biocidal 46 
product regulation (BPR) (http://eur-47 
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:0001:0123:EN:PDF 48 
accessed 24th November 2014) to regulate the authorisation and use of biocidal 49 
products throughout the EU, the total amount of microbicide use in the EU remains 50 
unknown (2). 51 
 52 
Of particular concern are formulations that contain microbicides at low 53 
concentrations which may increase the risk of selection for resistance amongst target 54 
or non-target microorganisms (2). Resistance or reduced susceptibility to 55 
microbicides and/or antibiotics as a result of exposure to low microbicide 56 
concentrations has been demonstrated extensively in the laboratory setting (3-7).  57 
Despite the lack of in vivo or in situ studies reporting a link between microbicide 58 
exposure and antibiotic resistance development, in vitro studies have clearly 59 
demonstrated the possibility of microbicide and antibiotic resistance development in 60 
bacteria. This has lead committees such as the Scientific Committee on Emerging 61 
and Newly Identified Health Risks (SCENIHR) to produce reports and opinions on 62 
the knowledge gaps and research concerns associated with resistance. In their 2010 63 
opinion paper SCENIHR stated that data on microbicide usage are lacking together 64 
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with an understanding of the microbicides most at risk for the development of 65 
bacterial resistance 66 
(http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_028.pdf, 67 
accessed 24th November 2014). SCENIHR recommended the standardisation of 68 
methodologies used to monitor resistance levels and suggested the development of a 69 
standard protocol that could determine the risk of resistance development in a 70 
particular microorganism as a result of microbicide exposure. 71 
 72 
In support of the requirement for such a protocol, the new BPR (EU 528/2012) states 73 
that it is a requirement of biocidal product manufacturers to provide information on 74 
the likelihood of resistance development to their product in target organisms. In 75 
particular the following articles state: 76 
 “(13) Active substances can, on basis of their intrinsic hazardous properties, be 77 
designated as candidates for substitution with other active substances, whenever such 78 
substances considered as efficient towards the targeted harmful organisms become 79 
available in sufficient variety to avoid the development of resistances amongst 80 
harmful organisms…” 81 
“(25) … The use of low-risk biocidal products should not lead to a high risk of 82 
developing resistance in target organisms.” 83 
 “(33) When biocidal products are being authorized, it is necessary to ensure that, 84 
when properly used for the purpose intended, they are sufficiently effective and have 85 
no unacceptable effect on the target organisms such as resistance...”. 86 
In addition, the U.S. Food and Drug Administration (FDA) has also issued a 87 
proposed rule to require manufacturers of antibacterial hand soaps and body washes 88 
to demonstrate that their products are safe for long-term daily use, more effective 89 
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than plain soap and water in preventing the spread of certain infections and do not 90 
select for resistance (http://www.gpo.gov/fdsys/pkg/FR-2013-12-17/pdf/2013-91 
29814.pdf accessed 24th November 2014). A standard protocol that could determine 92 
the risk of resistance development would allow microbicidal product manufacturers 93 
to provide this information to the BPR and FDA promptly and efficiently. 94 
Our work focuses on the development of such a protocol and has involved the 95 
assessment of several laboratory techniques that can be used to measure microbicide 96 
resistance (e.g. minimum inhibitory concentration (MIC)/minimum bactericidal 97 
concentration (MBC) determination, antibiotic susceptibility testing, and phenotype 98 
stability testing) in terms of ease of use, high throughput, cost and reproducibility. 99 
Our recommended protocol encompasses MIC, MBC and antibiotic susceptibility 100 
determination combined with bacterial phenotype stability testing as initial markers 101 
of bacterial microbicide resistance or antibiotic cross-resistance. This study aims to 102 
validate the use of these techniques in a combination protocol with the testing of 103 
three commercially available formulations and the corresponding active microbicides 104 
contained therein. 105 
 106 
 107 
 108 
MATERIALS AND METHODS 109 
Bacterial strains.  A range of Gram-negative bacteria was selected for the testing of 110 
three antimicrobial formulations and the corresponding microbicides contained 111 
within each formulation. The bacteria included Salmonella enterica serovar 112 
Typhimurium strains SL1344 and 14028S (obtained from the University of 113 
Birmingham, UK), Burkholderia cepacia (UL2P; Unilever culture collection, UK), 114 
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Klebsiella pneumoniae (UL13; Unilever culture collection, UK) and Pseudomonas 115 
aeruginosa (UL-7P; Unilever culture collection, UK). The 3 Unilever strains were 116 
selected as challenge organisms due to their routine use, propagation and handling in 117 
Unilever laboratories.  118 
 119 
Culture and storage of bacteria.  Liquid cultures of all strains were grown in 120 
tryptone soya broth (TSB) (Oxoid, Basingstoke, UK) at 37°C (± 1 °C). Strains were 121 
stored on protect beads (Fisher Scientific, Loughborough, UK) at -80 °C (± 1 °C) 122 
and restricted to a maximum of 2 subcultures from the original freezer stock prior to 123 
exposure to a given microbicide. Test inocula were prepared from harvesting an 124 
overnight TSB culture centrifuged at 5000 g for 10 min and re-suspended in 125 
deionised water (diH20). 126 
 127 
Formulations, actives and neutraliser.  A mouthwash (2 mg/mL chlorhexidine 128 
digluconate; CHG), eye make-up remover (1 mg/mL CHG) and a shampoo (5 129 
mg/mL benzalkonium chloride; BZC) were tested. Selection of these products was 130 
based on the fact that they are commonly used home and personal care products. The 131 
microbicides CHG and BZC (Sigma-Aldrich, Dorset, UK), the only microbicides 132 
contained within the three formulations, were also tested. The neutraliser used was 133 
composed of Tween 80 (30 g/L) and Asolectin (3 g/L) (both Sigma-Aldrich, Dorset, 134 
UK). Neutraliser efficacy for mouthwash, shampoo and eye make-up remover, and 135 
toxicity towards all strains was determined as described previously (3). 136 
 137 
Antimicrobial susceptibility testing 138 
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Suspension testing:  Test strains were exposed to each formulation and each 139 
microbicide at a concentration resulting in a 1-3 log10 reduction in CFU/mL, leaving 140 
sufficient survivors for further antimicrobial susceptibility testing. Suspension tests 141 
were carried out following the British Standard EN 1276 2009 protocol (8). Briefly, 142 
bacterial suspensions in deionised water (diH20) produced from overnight cultures 143 
were standardised to 1 x 108 CFU/mL. Suspensions were used within 15 minutes of 144 
preparation. One mL of standardised suspension was added to 9 mL of the desired 145 
formulation or active (diluted in diH20) at 1.25 times the required concentration. 146 
Concentrations tested were as follows: 0.000125 mg/mL mouthwash/CHG, 0.00015 147 
mg/mL shampoo/BZC and 1 mg/mL eye make-up remover/CHG. After exposure for 148 
1 min (the estimated length of time spent using each formulation by the consumer), 1 149 
mL of this suspension was removed and added to 9 mL of neutraliser. After 150 
neutralisation, suspensions were centrifuged at 5000 g for 10 min and the 151 
supernatant discarded. The remaining cells were then used in further antimicrobial 152 
susceptibility testing experiments. S. enterica strains SL1344 and 14028S were also 153 
exposed to low BZC and CHG concentrations ranging from 0.0001– 0.004 mg/mL 154 
for 5 min. 155 
 156 
Determination of the minimum inhibitory concentration (MIC). The MIC of each 157 
formulation/microbicide was determined for all strains before and after suspension 158 
test exposure to a given formulation/active, following the BS EN ISO: 20776-1 (9) 159 
protocol. Briefly, a 96 well microtitre plate (Sterilin Ltd, Newport, UK) containing 160 
doubling dilutions of a given formulation/active in TSB was set up. Concentration 161 
ranges were as follows: Mouthwash/CHG 2 – 0.001 mg/mL, shampoo/BZC 1.25– 162 
0.001 mg/mL, eye make-up remover/CHG 0.5 – 0.00048 mg/mL, CHG/BZC 163 
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(Salmonella strains only) 40 – 0.019 mg/mL. An overnight broth culture of each 164 
strain was standardised to 1 x 108 CFU/mL and 50 µL volumes of this were added to 165 
the microtitre plate. The plate was incubated for 24 h at 37°C. The MIC was defined 166 
as the lowest concentration of a formulation/microbicide at which no bacterial 167 
growth was observed visually on the microtitre plate. (Approximate cost to test one 168 
microbicide and one bacterium in triplicate: < 1€). 169 
 170 
Determination of the minimum bactericidal concentration (MBC). The MBC of 171 
each formulation/microbicide was also determined before and after suspension test 172 
exposure of each strain to a given formulation/active. Twenty µL of suspension was 173 
removed from each well of the MIC microtitre plate where no bacterial growth was 174 
observed and the two lowest formulation/active concentrations at which growth was 175 
observed, and added to 180 µL of neutraliser. Twenty-five µl of this suspension was 176 
then spotted on to tryptone soya agar (TSA) and incubated at 37°C for 24 h. The 177 
minimum bactericidal concentration was defined as the lowest formulation/active 178 
concentration where no bacterial growth was observed on the agar plate. 179 
(Approximate cost to test one microbicide and one bacterium in triplicate: < 1 €). 180 
 181 
 182 
Antibiotic susceptibility testing. The susceptibility of each strain to one or more of 183 
the following antibiotics was determined before and after suspension test exposure to 184 
a given formulation/microbicide following the British Society for Antimicrobial 185 
Chemotherapy (BSAC) disk diffusion protocol (10): chloramphenicol (50 µg), 186 
ampicillin (10 µg), ciprofloxacin (1 µg), ceftriaxone (30 µg), piperacillin (30 µg), 187 
ceftazidime (30 µg), imipenem (10 µg), meropenem (15 µg), tobramycin (10 µg), 188 
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aztreonam (30 µg) (all from Oxoid, Baskingstoke, UK). These antibiotics were 189 
selected due to their use as therapeutic agents in the treatment of infection with the 190 
organisms chosen for this study. There are no available BSAC susceptibility 191 
breakpoints for Burkholderia spp., so breakpoints for Pseudomonas spp. were used 192 
instead in the case of strain UL2P (B. cepacia). (Approximate cost to evaluate 193 
susceptibility of 1 strain to 6 antibiotics: < 2 €) 194 
 195 
Phenotype stability testing. The stability of any alterations in antimicrobial 196 
susceptibility observed after 5 min exposure of S. enterica strains SL1344 and 197 
14028S to a range of low CHG and BZC concentrations was investigated via the 24 198 
h subculture of surviving organisms through TSB +/- a low concentration of CHG or 199 
BZC as described previously (3).  200 
 201 
Data reproducibility. In order to determine the reproducibility of baseline and post-202 
exposure data obtained, the above experiments were performed on 3 separate 203 
occasions (each using 3 biological replicates) over a 6 month period, resulting in data 204 
values being a mean of 9 results. 205 
 206 
Statistical analysis. A Students t-test was used to compare MIC, MBC and antibiotic 207 
zone of inhibition sizes before and after microbicide exposure. 208 
 209 
RESULTS 210 
Three formulations and their corresponding microbicides were tested on three 211 
separate occasions over a 6 month period in order to determine if exposure to a given 212 
microbicidal product or microbicide resulted in an alteration in microbicide or 213 
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antibiotic susceptibility in test organisms. Data obtained on each occasion were 214 
compared in order to determine the reproducibility of the MIC, MBC and antibiotic 215 
susceptibility tests, and therefore validate the use of these tests as a high throughput 216 
and low cost initial approach in the determination of the risk of resistance 217 
development. The mean MIC and MBC for each test organism before and after 218 
exposure to mouthwash, eye make-up remover or shampoo and their corresponding 219 
microbicides (CHG, CHG, BZC) at the same concentration as that contained within 220 
the product are presented in FIG.1. Exposure to one of three formulations or their 221 
corresponding microbicides resulted in both increases and decreases in MIC and 222 
MBC in individual strains. In the case of shampoo and eye make-up remover an 223 
accurate MBC could not be determined as all 5 strains grew in the highest testable 224 
concentration of the formulation. The greatest increases in MBC were observed in S. 225 
enterica strain 14028S after exposure to 0.005 mg/mL CHG and mouthwash, and 226 
0.015 mg/mL BZC, all of which were found to be significantly different from 227 
baseline MBC values. However when considering the post-exposure MBC values 228 
observed (0.08, 0.05 and 0.05 mg/mL respectively) it is clear that these values are 229 
still below or equal to the concentrations of CHG and BZC present in the relevant 230 
formulations when considered as a worst case scenario of product dilution by the 231 
consumer. ‘Worst case’ dilution factors of 1 in 40 (mouthwash) and 1 in 100 232 
(shampoo) were estimated based on product use, e.g. rinsing with water. This would 233 
result in 0.05 mg/mL CHG in mouthwash and 0.05 mg/mL BZC in shampoo. An 234 
MBC of 0.50 mg/mL for BZC is also of less concern as the primary function of BZC 235 
in the shampoo is not as an antimicrobial, but as a surfactant.  Very few of the 236 
remaining observed changes in MIC or MBC were found to be statistically 237 
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significant (p≤0.05), nor did they approach the microbicide concentrations found in 238 
the formulations tested after ‘worst case’ product dilution by the consumer. 239 
An important factor in the validation of the use of MIC and MBC determination in 240 
an initial assessment of the risk of resistance development was the reproducibility of 241 
the data obtained. It is clear from FIG. 1 that both the baseline and post-exposure 242 
mean MIC and MBC values were highly reproducible across the 3 separate 243 
experiments, as indicated by the small standard deviations observed for each strain 244 
and formulation/pure active. Our protocol is based on performing MIC/MBC in two 245 
fold dilutions. Standard deviations were calculated based on the MIC or MBC 246 
values, which means an increase or decrease in MIC or MBC by one fold dilution 247 
will result in a large standard deviation. Error bars (representing SD) on the graphs 248 
displayed in FIG. 1 may only indicate an increase or decrease of one doubling 249 
dilution.  250 
 251 
There was no clinical change in susceptibility to any of the antibiotics tested after 1 252 
min exposure to all 3 formulations and their corresponding microbicides, in the case 253 
of all 5 strains (according to BSAC susceptibility breakpoints for 254 
Enterobacteriaceae/Pseudomonas spp. (10) (data not shown). In the case of some 255 
strains and antibiotics, statistically significant changes in the zone of inhibition size 256 
were observed. However these differences were often due to an increase in the mean 257 
zone of inhibition size and therefore an increase in antibiotic susceptibility [e.g. 258 
ciprofloxacin, chloramphenicol, ceftazidime in K. pneumoniae after exposure to 259 
mouthwash (0.050 mg/mL CHG) or ceftazidime in P. aeruginosa after exposure to 260 
shampoo (0.015 mg/mL BZC)]. A statistically significant reduction in the mean zone 261 
of inhibition size for aztreonam was observed in P. aeruginosa after exposure to 262 
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0.005 mg/mL CHG, 0.015 mg/mL BZC and 1 mg/mL CHG. However P. aeruginosa 263 
was already resistant to this antibiotic prior to microbicide exposure and therefore no 264 
clinical susceptibility change was observed. It was not possible to clearly determine 265 
if clinical changes in susceptibility were observed in B. cepacia, as there were no 266 
available breakpoints provided in the BSAC protocol, and clinical susceptibility was 267 
therefore based on Pseudomonas spp.  268 
Carrying out this experiment on 3 separate occasions over a 6-month period also 269 
allowed for an assessment of the reproducibility of the results obtained. The BSAC 270 
method produces consistent and reproducible baseline and post-exposure data (data 271 
not shown). 272 
 273 
S. enterica strains SL1344 and 14028S were also exposed to a range of low 274 
concentrations of CHG and BZC for 5 min before the antimicrobial susceptibility of 275 
surviving organisms was determined. Tables one and two show the baseline and post 276 
exposure values for SL1344 and 14028S respectively after 5 min exposure to a range 277 
of low CHG and BZC concentrations.  278 
In the case of both strains post-exposure MIC and MBC values for CHG and BZC 279 
were all significantly different from baseline MIC and MBC values (p≤0.05). For 280 
strain SL1344 the greatest increases in MIC and MBC were observed after 5 min 281 
exposure to 0.004 mg/mL CHG and 0.004 mg/mL BZC (Table 1). For strain 14028S 282 
exposure to 0.001 mg/mL CHG and 0.004 mg/mL BZC resulted in the greatest 283 
increases in MIC and MBC in surviving organisms (Table 2). The data appear highly 284 
reproducible across all 9 repeats in the case of both strains, as indicated by the low 285 
standard deviation values, supporting our recommendation of the use of MIC and 286 
MBC determination as an initial indicator of resistance development in bacteria. (As 287 
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discussed for FIG. 1, occasions where standard deviations appear larger are due to 288 
the use of doubling dilutions of a given microbicide/formulation during MIC/MBC 289 
testing). Susceptibility to a range of antibiotics was also determined for strains 290 
SL1344 and 14028S before and after exposure to low CHG and BZC concentrations. 291 
No alterations in antibiotic susceptibility were observed (data not shown). 292 
 293 
The stability of the increases in MBC observed after 5 min exposure of SL1344 and 294 
14028S to a range of low CHG and BZC concentrations was investigated via the 24 295 
h subculture of surviving organisms through TSB +/- a low concentration of CHG or 296 
BZC. Table 3 and 4 show the mean MBC values after 1, 5 and 10 subcultures of 297 
surviving organisms through TSB +/- CHG or BZC for SL1344 and 14028S 298 
respectively. The high MBC values observed after the initial 5 min exposure to CHG 299 
or BZC were lost after 1 subculture in the absence of CHG or BZC. In the presence 300 
of a low CHG or BZC concentration, MBC values also returned to baseline levels 301 
after 10 subcultures. This was thought to be due to cumulative damage to the cell or 302 
the fact that maintaining a high MBC was detrimental to cell survival. The instability 303 
of the increased MBC values suggested a low risk of stable resistance development 304 
to CHG or BZC in either S. enterica strain at the concentrations tested. The values 305 
obtained from the phenotype stability tests were reproducible between repeats (as 306 
indicated by the low standard deviation values in Tables 3 and 4) and the data 307 
therefore supports our recommendation of the use this technique as part of a protocol 308 
to predict microbicide resistance development. 309 
 310 
DISCUSSION 311 
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The principle aim of this work is to design a protocol that can predict bacterial 312 
microbicide resistance and antibiotic cross-resistance and give an indication of the 313 
risk of resistance development. The purpose of this study was to validate the use of 314 
MIC, MBC and antibiotic susceptibility determination before and after microbicide 315 
exposure, and phenotype stability testing for use in the initial prediction of bacterial 316 
microbicide resistance.  317 
The use of existing standard protocols for MIC, MBC and antibiotic susceptibility 318 
measurement (i.e. EN 1276, ISO 20776-1, BSAC disk diffusion method) helps to 319 
avoid data variability which has been observed previously with MIC values obtained 320 
using different methodologies. Schurmaans et al. (11) found that MIC values could 321 
vary by a factor of up to eight if small alterations were made to the method used. 322 
Phenotypic variability was avoided through the use of overnight broth cultures for 323 
susceptibility testing, rather than selecting single colonies from an agar plate, which 324 
has been demonstrated to result in phenotypic variability in Burkholderia cepacia 325 
(12), illustrating the importance of consistent inoculum preparation when performing 326 
susceptibility tests. In the work carried out here the inoculum was re-suspended in 327 
diH20 instead of tryptone sodium chloride (TSC) buffer as TSC has been seen to 328 
interfere with log reduction results due to carry over from the inoculum (unpublished 329 
data). However the inoculum was used within 15 min of preparation in diH20 to 330 
avoid subjecting bacterial cells to osmotic stress. 331 
The MIC, MBC and antibiotic susceptibility values for mouthwash, shampoo, eye 332 
make-up remover, CHG and BZC were found to be reproducible between separate 333 
experiments at the concentrations tested in all 5 test strains, confirming the 334 
appropriateness of using these standard protocols. We concluded that there is a very 335 
low risk of resistance development to the formulations and corresponding pure 336 
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actives tested, even in the case of the elevated MICs and MBCs observed in strains 337 
SL1344 and 14028S as these values were not stable in the absence or presence of 338 
CHG or BZC.  339 
The use of MIC and MBC in resistance prediction and making a comparison 340 
between baseline and post-exposure susceptibility data is supported by our previous 341 
work investigating the effect of cationic microbicide exposure on B. lata strain 383 342 
(3). Our protocol allows the testing of any isolate of interest  as data are always 343 
compared  for the individual isolate rather than general data for the given bacterial 344 
species. 345 
 346 
One of the criticisms of in vitro techniques used in microbicide resistance 347 
measurement is that experimental parameters such as microbicide concentration, 348 
exposure time, dilution on application and bioavailability are not reflective of in-use 349 
conditions (1, 13).  In our work we attempted to accurately reflect product use in 350 
terms of exposure time and product concentration (i.e. any dilution of the product as 351 
a result of its use). For the purpose of protocol development test concentrations used 352 
were considerably lower than those found in the original formulations (i.e. 353 
concentrations low enough to obtain surviving organisms), but should be kept 354 
realistic when using the techniques recommended here to predict and assess the risk 355 
of resistance development. Both formulations and the corresponding active 356 
microbicides were tested during protocol development in order to validate the 357 
different techniques used, but it must be emphasised that using such a protocol to 358 
predict resistance to pure actives alone may be of less relevance than testing the 359 
formulation as a whole, as multiple components of a formulation often contribute to 360 
the overall microbicidal effect, or could prove antagonistic in the formulation.  361 
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Although better representative of microbicide use, long-term (≥ 6 months) studies 362 
investigating the effect of exposure to commonly used household microbicides on 363 
antimicrobial susceptibility, have failed to demonstrate resistance development in 364 
isolated bacteria (14-17). These studies are also costly and do not allow for a prompt 365 
response to regulatory bodies. This suggests that in light of new regulatory 366 
expectations a compromise may be required, allowing the rapid generation of data 367 
and preliminary assessment of risk, using in vitro techniques based on existing 368 
standard methods whilst controlling parameters such as microbicide formulation, 369 
contact time and concentration in order to bring realism to the evaluation. The 370 
protocol proposed in this study aims to achieve this. 371 
 372 
A further recommendation of Maillard et al. (1) and SCENIHR (2) in the event of 373 
the observation of a reproducible change in microbicide susceptibility is the 374 
execution of further tests to understand the nature of the change. This could include 375 
molecular techniques to investigate changes to the transcriptome and proteome as a 376 
result of microbicide exposure. Genotypic alterations as a result of microbicide 377 
exposure and their potential as resistance markers have been investigated by 378 
numerous groups (18-20), and molecular techniques such as PCR and microarray 379 
technology have been successfully used to define microbicide resistance 380 
mechanisms.  Although useful, molecular techniques can be complex, costly and 381 
time consuming and we therefore do not recommend them as a core part of this 382 
predictive protocol. Taking this in to account, FIG. 2 shows the proposed protocol 383 
steps in the form of a decision tree, as well as potential steps in the event of 384 
observed, reproducible resistance. A stable increase in MIC or MBC or change in 385 
antibiotic susceptibility could result in risk of resistance development. It must be 386 
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emphasised that the exact level of risk can only be determined through further 387 
assessment. For example, a stable increase in MBC may not constitute a high level 388 
of risk if this new MBC does not approach the concentration of a particular 389 
microbicide intended for use (FIG. 2).  Some microbicides have a long history of 390 
use, and there is a large amount of literature studying their efficacy and any observed 391 
bacterial resistance, e.g. chlorhexidine, triclosan, benzalkonium chloride. For these 392 
microbicides there may be sufficient evidence available in the literature to support a 393 
weight of evidence assessment of the risk of resistance development, before 394 
considering the generation of new data on resistance (21, 22). 395 
 396 
Our findings and proposed approach for assessment of risk can be applicable to the 397 
wider use of microbicides in various settings where such compounds are applied. 398 
This approach is preventative and aimed at being predictive, thereby ensuring that 399 
microbicide-containing formulations are safe by design with regards to resistance 400 
and cross-resistance risks, either by enabling omission of an ingredient identified by 401 
the protocol as undesirable or by using the improved understanding of resistance and 402 
cross-resistance mechanisms  to design a formulation with an ingredient preventing 403 
the expression of a microbicide-relevant resistance mechanism (e.g. efflux pump 404 
inhibitors). Such a strategy has already been investigated and documented to 405 
decrease bacterial resistance to antibiotics (23). 406 
 407 
With regulatory bodies such as the US FDA and EU BPR requiring information on 408 
the propensity of microbicidal products to select for resistant bacteria, it is 409 
imperative that relevant, cost-effective, high throughput techniques are available in 410 
order for product manufacturers to provide this information. As global harmonisation 411 
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of protocols used to measure changes in microbicide susceptibility is now considered 412 
a key requirement in moving microbicidal research forward (1,2), we recommend, 413 
and here demonstrate, the efficacy of a protocol that allows the prediction of 414 
resistance development using simple, low cost and high throughput techniques.  415 
 416 
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TABLE 1: Mean baseline and post-exposure MIC and MBC values for strain SL1344 after 5 min exposure to a range of low CHG and BZC concentrations. N=9 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
520 
Biocide concentration (mg/mL) ± SD 
MIC/MBC 
(mg/mL) 
Baseline 0.004  
CHG 
0.001 
CHG 
0.0005 
CHG 
0.0001 
CHG 
0.004 
BZC 
0.001 
BZC 
0.0001 
BZC 
CHG MIC 0.03  ± 0.03 0.80 ± 0.00 0.80 ± 0.00 0.40 ± 0.00 0.80 ± 0.00 0.50 ± 2.00 0.40 ± 0.00 0.80 ± 0.00 
 
CHG MBC 0.10 ± 0.06 2.00 ± 0.90 2.00 ± 0.00 0.40 ± 0.00 1.00 ± 0.40 3.00 ± 0.00 2.00 ± 0.00 2.00 ± 1.00 
 
BZC MIC 0.03 ± 0.00 2.00 ± 0.00 0.30 ± 0.20 0.10 ± 0.00 0.70 ± 1.00 3.00 ± 1.00 0.80 ± 0.00 0.70 ± 1.00 
 
BZC MBC 0.03 ± 0.03 2.00 ± 0.00 0.50 ± 0.20 2.00 ± 2.00 1.30 ± 2.00 8.00 ± 0.00 2.00 ± 0.00 3.00 ± 2.00 
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 521 
TABLE 2: Mean baseline and post-exposure MIC and MBC values for strain 14028S after 5 min exposure to a range of low CHG and BZC concentrations. N=9522 
Biocide concentration (mg/mL) ± SD 
MIC/MBC 
(mg/mL ± SD) 
 
Baseline 0.005  
CHG 
0.001 
CHG 
0.015 
BZC 
0.004 
BZC 
CHG MIC 0.030  ± 0.03 0.10 ± 0.00 1.00 ± 0.00 0.40 ± 0.00 0.80 ± 0.00 
 
CHG MBC 0.06 ± 0.03 1.00 ± 0.90 20.00 ± 0.00 50.00 ± 0.00 3.00 ± 0.00 
 
BZC MIC 0.04 ± 0.03 0.80 ± 0.00 0.10 ± 0.00 0.80 ± 0.00 2.00 ± 0.00 
 
BZC MBC 0.08 ± 0.02 1.00 ± 0.00 2.00 ± 0.60 1.00 ± 0.00 20.00 ± 0.90 
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TABLE 3: Mean baseline and post-exposure MBC values for strain SL1344 after 1, 5 and 10 subcultures in TSB +/- 0.004 mg/mL CHG or BZC. 523 
 524 
SC = subculture         * = significantly different from baseline (p≤0.05) 525 
 
Baseline  
MBC (mg/mL) 
5 min CHG 
0.004  
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
 (CHG) 
5 SC 
(CHG) 
10 SC 
(CHG) 
CHG MBC 
(mg/mL ± SD) 
 
0.10 ± 0.90 
 
5.00 ± 0.00* 
 
0.08 ± 0.00 
 
0.09 ± 0.00 
 
0.06 ± 0.00 
 
0.15 ± 0.40 
 
0.10 ± 0.40 
 
0.10 ± 0.00 
 
BZC MBC 
(mg/mL ± SD) 0.03 ± 0.00 1.50 ± 0.00* 0.04 ± 0.00 0.06 ± 0.00 0.06 ± 0.00 0.19 ± 0.00* 0.50 ± 0.20* 0.06 ± 0.00 
 
Baseline  
MBC (mg/mL) 
5 min BZC 
0.004  
1 SC 
 
5 SC 
 
10 SC 
 
1  SC 
(BZC) 
5  SC 
(BZC) 
10  SC 
(BZC) 
CHG MBC 
(mg/mL ± SD) 
 
0.10 ± 0.90 
 
5.00 ± 0.00* 
 
0.20 ± 0.30 
 
0.10 ± 0.00 
 
0.10 ± 0.00 
 
0.80 ± 0.40* 
 
0.80 ± 0.40* 
 
0.10 ± 0.00 
 
BZC MBC 
(mg/mL ± SD) 0.03 ± 0.00 3.00* ± 0.00 0.06 ± 0.00 0.06 ± 0.00 0.06 ± 0.00 0.78 ± 0.00* 0.60 ± 0.20* 0.03 ± 0.00 
 526 
 527 
 528 
 529 
 530 
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TABLE 4: Mean baseline and post-exposure MBC values for strain 14028S after 1, 5 and 10 subcultures in TSB +/- 0.004 mg/mL CHG or BZC. 531 
SC = subculture         * = significantly different from baseline (p≤0.05) 532 
 533 
 
Baseline  
MBC (mg/mL) 
5 min CHG 
0.001 
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
(CHG) 
5 SC 
(CHG) 
10 SC 
(CHG) 
CHG MBC 
(mg/mL ± SD) 
 
0.06 ± 0.03 
 
5.00 ± 0.00* 
 
0.01 ± 0.00 
 
0.06 ± 0.00 
 
0.09 ± 0.00 
 
0.80 ± 0.40* 
 
0.80 ± 0.40* 
 
0.06 ± 0.00 
 
BZC MBC 
(mg/mL ± SD) 0.08 ± 0.02 3.00 ± 0.00* 0.06 ± 0.00 0.07 ± 0.00 0.06 ± 0.00 0.19 ± 0.00* 0.20 ± 0.00* 0.06 ± 0.00 
 
Baseline  
MBC (mg/mL) 
5 min BZC 
0.004  
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
 (BZC) 
5 SC 
 (BZC) 
10 SC 
(BZC) 
CHG MBC 
(mg/mL ± SD) 
 
0.06 ± 0.03 
 
5.00 ± 0.00* 
 
0.06 ± 0.00 
 
0.05 ± 0.00 
 
0.06 ± 0.00 
 
0.40 ± 0.20* 
 
0.70 ± 0.70* 
 
0.06 ± 0.00 
 
BZC MBC 
(mg/mL ± SD) 0.08 ± 0.02 3.00 ± 0.00* 0.07 ± 0.00 0.04 ± 0.00 0.06 ± 0.00 0.19 ± 0.00* 0.20 ± 0.00* 0.06 ± 0.00 
 534 
 535 
 536 
 537 
 538 
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FIG 1: MIC and MBC values for 5 test organisms re and after exposure to 3 formulations and their corresponding pure actives. N=9. Blue = baseline MIC. Red = post-540 
exposure MIC. Green = baseline MBC. Purple = post-exposure MBC. Error bars correspond to the SD. MIC and MBC were performed in two fold dilution (see text for 541 
detailed information). A) 0.005 mg/ml CHG; B) mouthwash (0.005 mg/mL CHG); C) 1 mg/mL CHG; D) Eye-maker remover (neat: 1 mg/mL CHG); E) 0.015 mg/mL 542 
BZC; F) Shampoo (0.015  543 
 544 
545 
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Figure 3: Proposed protocol for use in the prediction of bacterial microbicide resistance. Grey boxes are examples of further work that could be carried out to investigate 546 
mechanisms behind changes in antimicrobial susceptibility. 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
Mechanisms of resistance? 
Efflux assays 
Does efflux activity increase? 
Membrane protein expression 
Change in outer membrane 
proteins? 
Microarray 
Identification of potential 
marker genes 
Real time PCR 
Confirmation of microarray changes  
Identification of marker gene 
Phenotype stability testing
Are the observed changes stable? 
No 
Yes
Further 
investigate 
risk
2 
MIC/MBC/antibiotic susceptibility 
Is there an increase in MIC/MBC? 
Is there a change in antibiotic susceptibility? 
After exposure to a product under realistic conditions
1 
No 
Low 
Risk 
Yes Decision point:  
• Evaluate increased MIC/MBC against realistic, in-use concentrations 
• Compare decreased antibiotic susceptibility against clinical breakpoint 
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Footnotes for figure 3 564 
1
 Realistic conditions refers to those under which the product will be used. Factors such as concentration, contact time and product formulation should be considered in 565
order to represent product use as accurately as possible. 566 
2 
If reproducible and phenotypically stable changes in antimicrobial susceptibility are observed after exposure to a particular product under realistic, in-use conditions, 567 
further investigation into the risk can be carried out. This may involve the elucidation of possible mechanisms behind susceptibility changes such as the examples shown in 568 
the grey boxes in figure 3, leading to better understanding of the level of risk. This investigation could be extended beyond the examples given in figure 3, and could 569 
include the exploration of additional resistance markers and the use of additional techniques. 570 
 571 
